EpiPen price hikes may be causing outrage, but those pale in comparison to the huge increases that Mylan Laboratories took on dozens of other medicines earlier this year.

For instance, the company raised the price of ursodiol, a generic medicine used to treat gallstones, by 542 percent. There was also a 400 percent boost in the price for dicyclomine, which combats irritable bowel syndrome, and a 312 percent increase for metoclopramide, a generic drug that treats gastroesophageal reflux disease.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • In my opinion actual increases in retail prices are more telling. One example is a Mylan product, first patented in 2006, of a transdermal skin patch containing selegiline (EMSAM) used to treat major depressive disorder, Parkinson’s disease, and other nervous system conditions. This patent for Emsam currently expires in 2018. This is the earliest possible date that a generic version of Emsam could become available. However, there are other circumstances that could come up to extend the exclusivity period of Emsam beyond 2018. These circumstances could include things such as other patents for specific Emsam uses or lawsuits.

    In 2008 the retail price of EMSAM for a 30-day supply was approximately $493. In 2012 it was approximately $628. Sometime in 2015, the retail price was increased to approximately $1,600 ($53/patch)! Sure, as is the customary public relations business strategy of Mylan, a coupon is available on its website, but even at a discount of $500/month who can afford it when most of the insurance companies have moved this medication from a preferred/covered medication to a non-preferred/not covered medication?

  • Quality and Affordability of generics must go side by side with sustainability of their production on a minimum economic scale.

    • I hope their greed burns them bad. They are stealing from the general public who pays for this s*** with the outrageous unaffordable insurance premiums for their unaffordable drug prescriptions that truly cost pennies to the dollar to make. Insurance companies should not be involved in prescription drugs. It would be affordable if drug companies like this had to base their prices on what people can afford rather than hiking the price because insurance will pay any price leaving the ones on premiums with the bill plus profits.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy